1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Ammassari, A., Antinori, A., Aloisi, M. S., Trotta, M. P., Murri, R., Bartoli, L., et al. (2004). Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45 394–402.
3. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Chesney, M. A., and Moss, A. (2001). Comparing objective measures of adherence to HIV antiretroviral therapy: Electronic medication monitors and unannounced pill counts. AIDS and Behavior, 5 275–281.
4. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14 357–366.
5. Breslau, N., Davis, G., Andreski, P., Federman, B., and Anthony, J. (1998). Epidemiological findings on posttraumatic stress disorder and co-morbid disorders in the general population. In B. P. Dohrenwend (Ed.), Adversity, stress, & psychopathology (pp. 319–330). London: Oxford University Press.